S&P 500   0.56 (+0.00%)
DOW   0.56 (+0.00%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+0.00%)
DOW   0.56 (+0.00%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+0.00%)
DOW   0.56 (+0.00%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+0.00%)
DOW   0.56 (+0.00%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
Log in

NASDAQ:VIVOMeridian Bioscience Stock Price, Forecast & News

$25.99
+1.50 (+6.12 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$24.60
Now: $25.99
$26.14
50-Day Range
$16.88
MA: $22.51
$24.95
52-Week Range
$5.51
Now: $25.99
$26.14
Volume581,270 shs
Average Volume766,469 shs
Market Capitalization$1.11 billion
P/E Ratio50.96
Dividend YieldN/A
Beta0.94
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; rapid fluorescence-based immunoassay platform under the Curian brand; rapid single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare and PediaStat brands. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of gastrointestinal assays, including tests for C. difficile, Enterohemorrhagic E. coli, Campylobacter jejuni, H. pylori, Cryptosporidium, giardia lamblia, and calprotectin; respiratory illness assays, such as tests for Group A Streptococcus, Influenza, M. pneumoniae, Bordetella pertussis, and respiratory syncytial virus; blood chemistry assays; and tests for Group B Streptococcus, Chlamydia trachomatis, Neisseria gonorrhea, Herpes Simplex Virus Type 1 and Type 2, and Malaria. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by researchers, agri-bio companies, and IVD manufacturing companies. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Read More
Meridian Bioscience logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.94 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:VIVO
CUSIP58958410
Phone513-271-3700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$201.01 million
Cash Flow$0.97 per share
Book Value$4.47 per share

Profitability

Net Income$24.38 million

Miscellaneous

Employees660
Market Cap$1.11 billion
Next Earnings Date8/7/2020 (Confirmed)
OptionableOptionable
$25.99
+1.50 (+6.12 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VIVO News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions

How has Meridian Bioscience's stock been impacted by COVID-19 (Coronavirus)?

Meridian Bioscience's stock was trading at $6.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VIVO stock has increased by 304.2% and is now trading at $25.99.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Meridian Bioscience?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Meridian Bioscience
.

When is Meridian Bioscience's next earnings date?

Meridian Bioscience is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020.
View our earnings forecast for Meridian Bioscience
.

How can I listen to Meridian Bioscience's earnings call?

Meridian Bioscience will be holding an earnings conference call on Friday, August 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) announced its quarterly earnings data on Friday, May, 8th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.08 by $0.15. The firm had revenue of $57.30 million for the quarter, compared to analysts' expectations of $57 million. Meridian Bioscience had a net margin of 10.47% and a return on equity of 13.59%.
View Meridian Bioscience's earnings history
.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience issued an update on its FY 2020 Pre-Market earnings guidance on Friday, May, 8th. The company provided earnings per share (EPS) guidance of 0.70-0.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.29. The company issued revenue guidance of $230-236 million, compared to the consensus revenue estimate of $197.13 million.

What price target have analysts set for VIVO?

3 brokerages have issued 12-month price objectives for Meridian Bioscience's stock. Their forecasts range from $8.00 to $34.00. On average, they anticipate Meridian Bioscience's stock price to reach $21.00 in the next year. This suggests that the stock has a possible downside of 19.2%.
View analysts' price targets for Meridian Bioscience
.

Has Meridian Bioscience been receiving favorable news coverage?

News coverage about VIVO stock has trended extremely negative on Monday, InfoTrie reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Meridian Bioscience earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
View the latest news about Meridian Bioscience
.

Are investors shorting Meridian Bioscience?

Meridian Bioscience saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 2,650,000 shares, a decline of 14.5% from the June 30th total of 3,100,000 shares. Based on an average trading volume of 864,700 shares, the short-interest ratio is currently 3.1 days. Approximately 6.3% of the company's stock are sold short.
View Meridian Bioscience's Current Options Chain
.

Who are some of Meridian Bioscience's key competitors?

What other stocks do shareholders of Meridian Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), Amgen (AMGN), Inovio Pharmaceuticals (INO), Procter & Gamble (PG) and Cara Therapeutics (CARA).

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the following people:
  • Mr. John P. Kenny, Pres, CEO, Exec. VP of Diagnostics Bus. Unit & Director (Age 51, Pay $831.14k)
  • Mr. Bryan Baldasare, Exec. VP, Chief Accounting Officer, CFO & Sec.
  • Dr. Lourdes G. Weltzien, Exec. VP of Life Science Bus. Unit
  • Ms. Melissa A. Lueke, Consultant (Age 57, Pay $190.34k)
  • Mr. Jeff Pinkston, Director of Corp. Fin.

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

Who are Meridian Bioscience's major shareholders?

Meridian Bioscience's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Raymond James & Associates (0.26%), Wedge Capital Management L L P NC (0.24%), First Trust Advisors LP (0.20%), Mackay Shields LLC (0.19%), Moody Aldrich Partners LLC (0.13%) and 6 Meridian (0.11%). Company insiders that own Meridian Bioscience stock include Bryan T Baldasare, David Phillips, Dwight E Ellingwood, Felicia Williams, James M Anderson, John Mccune Jr Rice, John Mcilwraith, John P Kenny and Lawrence Baldini.
View institutional ownership trends for Meridian Bioscience
.

Which major investors are selling Meridian Bioscience stock?

VIVO stock was sold by a variety of institutional investors in the last quarter, including 6 Meridian, Brinker Capital Inc., and UBS Group AG.
View insider buying and selling activity for Meridian Bioscience
.

Which major investors are buying Meridian Bioscience stock?

VIVO stock was bought by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Mackay Shields LLC, Moody Aldrich Partners LLC, Strs Ohio, Exchange Traded Concepts LLC, MERIAN GLOBAL INVESTORS UK Ltd, Fox Run Management L.L.C., and SG Americas Securities LLC. Company insiders that have bought Meridian Bioscience stock in the last two years include Bryan T Baldasare, David Phillips, Dwight E Ellingwood, Felicia Williams, James M Anderson, John Mccune Jr Rice, John Mcilwraith, and John P Kenny.
View insider buying and selling activity for Meridian Bioscience
.

How do I buy shares of Meridian Bioscience?

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $25.99.

How big of a company is Meridian Bioscience?

Meridian Bioscience has a market capitalization of $1.11 billion and generates $201.01 million in revenue each year. The company earns $24.38 million in net income (profit) each year or $0.68 on an earnings per share basis. Meridian Bioscience employs 660 workers across the globe.

What is Meridian Bioscience's official website?

The official website for Meridian Bioscience is www.meridianbioscience.com.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.